Primer: Suzhou Genhouse Bio (SGHB HK) - Aug 2026
Suzhou Genhouse Bio is a clinical-stage biopharmaceutical company with a strategic focus on developing innovative small-molecule oncology...
94 Views
Suzhou Genhouse Bio (SGHB HK): Synthetic Expert Call Transcript (10 Aug 2026)
Gilead’s $80 million upfront payment for MAT2A inhibitor GH31 validates Genhouse's synthetic lethality platform but creates a critical strategic...
115 Views
IPO Databook: Suzhou Genhouse Bio (HK) - Aug 2026
Suzhou Genhouse Bio Co., Ltd., founded in May 2014, develops innovative oncology drug candidates, focusing on RAS signaling pathways and...
128 Views
Suzhou Genhouse Bio (勤浩医药) Pre-IPO: Moderate Innovation, Capped by Combination Economics
Suzhou Genhouse Bio plans to raise over USD100m through a Hong Kong listing with Huatai as the sponsor. We look at their core product GH21, their...
194 Views
Aequitas ECM Weekly (16 March 2026)- Past A/H Trends, Delton, Raajmarg, Ringpai, FS.com, Everdisplay
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
303 Views
No more insights